Biophytis SA · EURONEXT:ALBPS
Biophytis SA — JPM 2018
31 slides from Biophytis SA's conference presentation, January 2018

Slide 1: New Therapeutics for Diseases of Aging
biophytis NEW THERAPEUTICS FOR DISEASES OF AGING THE BIOTECH SPECIALISED IN DISEASES OF AGING

Slide 2: Disclaimer
DISCLAIMER Important Information and Forward Looking Statements • BIOPHYTIS IS A PUBLIC COMPANY LISTED ON THE ALTERNEXT MARKET OF EURONEXT PARIS STOCK EXCHANGE SINCE JULY 13, 2015. • THIS DOCUMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER FOR SALE OR SUBSCRIPTION OF OR SOLICITATION OF ANY OFFER

Slide 3: Corporate Overview
CORPORATE OVERVIEW BIOPHYTIS is a public company listed on Euronext Growth (Paris, France) • Share price (January 2nd 2018): €4,72 • Shares outstanding: 13,463,413 • Market capitalization: €63 M • €16 M raised in 2015; €28 M raised in 2017 BIOPHYTIS is advancing two drug candidates into Phase II SAR

Slide 4: A Seasoned Management Team
THE TEAM Stanislas VEILLET René LAFONT Founder & CEO Co-founder & CSO • PhD in genetics, AgroParisTech • Professor emeritus at alumnus Sorbonne Université • 15+ years in R&D management • Former Dean of the life (Monsanto, Pharmacia, sciences department Danone) • 170+ peer-reviewed • Created Biophyti

Slide 5: Drug Discovery & Development Strategy
DRUG DISCOVERY & DEVELOPMENT STRATEGY First generation Second generation • Active principles derived • New chemical entities from plant substances • Optimized • Preclinical proof of pharmacology concept • IP on composition of • Well tolerated in matter humans • IP on use and process Biophytis has id

Slide 6: Pipeline
blophytis PIPELINE CANDIDATES INDICATION PRECLINICAL | pHasE: | PHASE Il | PHASE | SARCONEOS SARCOPENIA ee DYSTROPHIES ACTIVATORS > —=)> MACUNEOS

Slide 7: Scientific Board
SCIENTIFIC BOARD Pr. Jean MARIANI Pr. René LAFONT Pr. José SAHEL Director of Institut de la Professor emeritus Director of longévité Charles Foix Former Dean of the life Institut de la sciences department Vision WORLD CLASS SCIENTIFIC LEADERS CONTRIBUTE TO THE DEVELOPMENT OF OUR DRUG CANDIDATES Dr.

Slide 8: MAS Activators and Muscular Diseases
MAS ACTIVATORS AND MUSCULAR DISEASES GERIATRIC CHRONIC DISEASE: SARCOPENIA PAEDIATRIC ORPHAN DISEASE DUCHENNE’S MUSCULAR DYSTROPHY (DMD)

Slide 9: Renin Angiotensin System (RAS) and Muscle Anabolism
RENIN ANGIOTENSIN SYSTEM (RAS) AND MUSCLE ANABOLISM Targeting RAS stimulates anabolism in muscle and has potential for the treatment of chronic or genetic muscle disorders 9

Slide 10: MAS Activation
MAS ACTIVATION SARCONEOS is a potent MAS activator that stimulates protein synthesis, energy production and regeneration in muscle 10

Slide 11: Sarcopenia
SARCOPENIA • Definition: Low muscle strength and low muscle mass (FNIH criteria) ICD-10 Code: M62.84 • Prevalence: 50M patients Estimated at 5 – 10% in >65 years old • Standard of Care: 30 minutes physical exercise / day No currently approved medication Drug candidates in development Examples Myosta

Slide 12: Sarconeos: Proof of Concept in Animals
SARCONEOS: PROOF OF CONCEPT IN ANIMALS SARCONEOS compensates the effect of ageing SARCONEOS stimulates anabolism in on muscle functionality and mobility muscle Increase in protein quantity in muscle Increase in running speed in old mice Inhibition of myostatin expression in muscle SARCONEOS stimulat

Slide 13: Sarconeos: Proof of Activity in Nutritional Trial
SARCONEOS: PROOF OF ACTIVITY IN NUTRITIONAL TRIAL QUINOLIA – Safety, PK and pharmacodynamic parameters in obese healthy volunteers • 58 subjects, double-blind, placebo-controlled, nutrition study (dieting) • Oral administration (40 mg/day) for 12 weeks (6 weeks hypocaloric dieting) • No serious adve

Slide 14: Sarconeos: Proof of Safety in Phase I Study
SARCONEOS: PROOF OF SAFETY IN PHASE I STUDY SARA-PK – Phase 1 – Safety, PK and PD in elderly healthy volunteers • 54 elderly subjects (>65 years), combined SAD (24 elderly and young subjects) + MAD step (30 elderly subjects) • MAD after oral administration of 350 mg/day, 700 mg/day or 900 mg/day for

Slide 15: SARA: Phase 2b International Clinical Program
SARA: PHASE 2b INTERNATIONAL CLINICAL PROGRAM SARA-OBS - Observational study • Multicentric observational study: eight clinical centers in Europe and the US • Recruitment of sarcopenic patients in Europe and US on going • 300 sarcopenic patients: Foundation of NIH inclusion criteria for sarcopenia •

Slide 16: Duchenne's Muscular Dystrophy (DMD)
DUCHENNE’S MUSCULAR DYSTROPHY (DMD) • Definition: Genetic disease characterized by progressive muscle degeneration • Prevalence: Around 5 per 100,000 males • Incidence: 1 in 3,500 male births • Standard of Care: Corticosteroids Drug candidates in development Examples Genetic and cell therapy Exon Sk

Slide 17: Sarconeos: Proof of Concept in Animals
SARCONEOS: PROOF OF CONCEPT IN ANIMALS SARCONEOS improves exercise tolerance in mdx SARCONEOS reduces fibrosis and mice lesional profile in mdx mice muscles Lesional profile 1200 Control 1000 mdx mdx Sarconeos Control SARCONEOS strongly improves muscle function and decreases muscle fibrosis in the s

Slide 18: Sarconeos: Clinical Development Plan in DMD
SARCONEOS: CLINICAL DEVELOPMENT PLAN IN DUCHENNE’S MUSCULAR DYSTROPHY Paediatric PK Study • Phase 1 trial in ambulant Duchenne boys • SAD, MAD Interventional Phase 2B trial • Multicentric international clinical trial • Ambulant Duchenne boys 18 19

Slide 19: PPAR Activators and Retinal Diseases
- PPAR ACTIVATORS AND \__ RETINAL DISEASES g CHRONIC DISEASE: | DRY AGE-RELATED MACULAR DEGENERATION (AMD) | PAEDIATRIC ORPHAN DISEASE: STARGARDT’S DISEASE

Slide 20: Photo-Oxidative Stress and Macular Degeneration
PHOTO-OXIDATIVE STRESS AND MACULAR DEGENERATION A2E and oxydative stress • A2E is a derivative of visual pigment • A2E accumulates in Retinal Pigment Epithelium (RPE) cells • A2E is a very reactive molecule that causes oxidative stress with exposure to light, leading to macular degeneration Photo-ox

Slide 21: PPAR Activation
PPAR ACTIVATION MACUNEOS activates PPAR nuclear receptors and protects the retina from oxidative stress associated with accumulation of A2E. • Cell death • Free radicals production • VEGF production • Inflammation MACUNEOS is an activator of PPARs and limits the degeneration of the retina ca

Slide 22: Dry Age-Related Macular Degeneration (AMD)
DRY AGE-RELATED MACULAR DEGENERATION (AMD) • Definition: All forms of AMD which are not neovascular and exsudative • Prevalence: Estimated at 20M globally • Standard of Care: Zinc + Vitamines C/E (nutraceuticals) Drug candidates in development Examples Anti-complement factor antibodies Lampaluzimab

Slide 23: Macuneos: Proof of Concept in Animals
MACUNEOS: PROOF OF CONCEPT IN ANIMALS MACUNEOS preserves the retina’s functionality and MACUNEOS preserves the number of layers of limits the A2E accumulation after chronic oral photoreceptors after a light stress (Blue light administration (ABCA4-/- RDH8-/- mice model) rat model) MACUNEOS protects

Slide 24: Macuneos: Safety and Proof of Concept in Humans
MACUNEOS: SAFETY AND PROOF OF CONCEPT IN HUMANS BIXILIA –Safety and PK in healthy volunteers • 47 healthy volunteers • Oral administration (35 mg/day) for 12 weeks • Double-blind, placebo-controlled, nutrition study • No serious adverse event • Achieved target for bioavailability MACA-PK – Phase 1/2

Slide 25: MACA: Phase 2b International Clinical Program
MACA: PHASE 2B INTERNATIONAL CLINICAL PROGRAM MACA-OBS – Observational study in patients with dry AMD • Multicentric observational study: clinical centers in Europe and the US • 100 patients suffering of intermediate dry AMD • Duration: 6 months • Endpoints: atrophic lesion size, ERG, visual acuity

Slide 26: Stargardt's Disease
STARGARDT’S DISEASE • Definition: Genetically determined Juvenile Macular Degeneration • Prevalence: Estimated at 1 in 10,000 • Standard of Care: Eyeglasses / Sunglasses Currently no approved therapeutic Drug Candidates in Development MACUNEOS preserves the retina structure after intra-vitreal injec

Slide 27: Value Creation News Flow
VALUE CREATION NEWS FLOW SARCONEOS in SARCOPENIA • H1 18: SARA-OBS: Interim results of the observational phase, in Europe and US • H1 18: SARA-INT: Initiation of the interventional Phase 2b SARA • H2 18: SARA-INT: Interim results of the interventional Phase 2b SARA (DSMB) • H2 18: SARA-INT: Results

Slide 28: A Board of Directors with Complementary Profiles
THE BOARD OF DIRECTORS Jean M. Franchi Stanislas VEILLET Marie-Claire JANAILHAC- Independant Board Chairman of the FRITCH Member Board Independant Board • BA in Finance in • PhD in genetics, Member Hofstra alumnus AgroParisTech • HEC alumnus • CFO for Merrimack alumnus • President of the Board, Phar

Slide 29: Capital Structure
CAPITAL STRUCTURE Stock profile • Market: Euronext Growth of Euronext Paris • Ticker: ALBPS • Shares outstanding: 13,463,413 • Share price (January 2d 2018): €4,72/share • Market Capitalization: €63 M 29 29

Slide 30: Highlights
HIGHLIGHTS SARCONEOS to treat sarcopenia and Duchenne’s Disease 1 • SARA-INT Phase 2b trial about to start H1 2018, reporting H2 2018 • DMD clinical program planned to start H2 2018 MACUNEOS to treat dry AMD and Stargardt’s Disease 2 • MACA-PK Phase 1 study about to start H1 2018, reporting H2 2018

Slide 31: Thank you
Thank you Investors contact: investors@biophytis.com 31
Source: Internet Archive copy of biophytis.com
More decks from Biophytis SA
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (March 2026)21 slides · March 2026
Investor Presentation (March 2026)21 slides · March 2026
Investor Presentation (January 2025)32 slides · January 2025
Investor Presentation (December 2024)48 slides · Dec 6, 2024